UPDATE: CORRECTION: Stifel Reiterates Buy Rating on SAGE Therapeutics (SAGE), "Approvability of zuranolone in MDD" Remains Key Question
Tweet Send to a Friend
(Updated - June 1, 2022 7:54 AM EDT)
Stifel analyst Paul Matteis reiterated a Buy rating on SAGE Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Stifel analyst Paul Matteis reiterated a Buy rating on SAGE Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
